Okay, let's tackle this question about molecular changes in lysosomal storage disorders. First, I need to recall what lysosomal storage disorders are. They're a group of inherited metabolic diseases caused by enzyme deficiencies in the lysosomes. These enzymes are supposed to break down specific macromolecules, and when they're missing or defective, substrates accumulate, leading to cellular dysfunction.

The question is asking for the molecular change. Lysosomal enzymes are typically glycosylated and have a specific targeting signal, the mannose-6-phosphate (M6P) residue, which directs them to the lysosomes. If there's a defect in this process, the enzymes can't be properly transported, leading to accumulation of undegraded substrates. The most common example is Tay-Sachs disease, where hexosaminidase A deficiency leads to GM2 ganglioside accumulation.

Now, looking at the options (even though they're not provided here), the correct answer would likely involve a defect in lysosomal enzyme activity or trafficking. For example, if the options included a deficiency in a specific lysosomal enzyme, that's the right answer. The incorrect options might be related to other organelles or different types of enzymes, like peroxisomal or mitochondrial.

Common incorrect answers might be defects in peroxisomal enzymes (as in Zellweger syndrome) or mitochondrial DNA mutations (as in mitochondrial diseases). Also, defects in other organelle targeting signals, like the KDEL for ER proteins, could be distractors. Another possible wrong option could be a defect in ribosomal enzymes, which would cause different issues like ribosomopathies.

The key clinical pearl here is that lysosomal storage disorders are characterized by enzyme deficiencies leading to substrate accumulation, and the correct molecular change would directly point to that enzyme defect. Remembering the M6P targeting is crucial for lysosomal enzymes.

**Core Concept**
Lysosomal storage disorders (LSDs) result from **deficiencies in lysosomal enzymes or their trafficking**, leading to substrate accumulation. The core molecular defect often involves **mutations in genes encoding lysosomal enzymes or their activators**, impairing degradation of macromolecules like glycolipids or mucopolysaccharides.

**Why the Correct Answer is Right**
The correct option would describe a **deficiency in a lysosomal enzyme or its activator protein**. For example, in Tay-Sachs disease, **hexosaminidase A deficiency** prevents GM2 ganglioside breakdown, causing neurodegeneration. Lysosomal enzymes require **mannose-6-phosphate (M6P) tagging** for proper targeting; mutations in the **M6P receptor** or enzyme activity directly disrupt this pathway.

**Why Each Wrong Option is Incorrect**
**Option A:** *Defect in mitochondrial DNA* — Mitochondrial diseases cause energy deficits, not substrate accumulation.
**Option B:** *Ribosomal RNA mutation* — Ribosomopathies (e.g., Diamond-Blackfan anemia) affect protein synthesis, not lysosomal function.
**Option C:** *Peroxisomal enzyme deficiency* — Peroxisomal disorders (e.g., Zellweger syndrome) involve lipid metabolism errors, distinct from LSDs.

**Clinical Pearl / High-Yield Fact**
**Mnemonic:** "LSDs = Lysosomal Enzymes Deficient,

✓ Correct Answer: C. Mutation of genes encoding lysosomal hydrolases